the allyl group may be compensated for by better transport into the bacterial cell. In addition to the SARanalysis, we demonstrated that the ineffectiveness of hygromycin A against Gram-negative enteric bacteria such as Escherichia coli is mainly due to the efflux mechanism (Acr A/B pump) existing widely amongthe enteric bacteria rather than the impermeablebarrier of the outer membrane. . The analogs were also tested in a S. hyodysenteriae whole cell assay to determine JUNE 1997 MICs and the active analogs amongthem were further studied in an antibacterial spectrum assay. Wealso demonstrated that the lack of anti-Gramnegative enteric activity of hygromycin A is caused by Acr A/B efflux pump mechanism existing widely among these bacteria.
Materials and Methods

Bacterial Strains
Escherichia coli K12 D10 {met, rna) was used for the S-30 and chromosomal DNApreparation. E. coli W4680 (F" AlacZ399 rpsL45, rpsLHO, melB4) and WZM120 (same as W4680; AacrAB\:Tn903kanr) were obtained from J. E. Hearst, University of California, Berkeley13 
Anti-S. hyodysenteriae Microdilution Assay
The assay method used here was reported previously and was based on the measurement of S. hyodysenteriae hemolysin production which was well correlated to bacterial growth17). A hygromycin A analog was considered active if it inhibited the S. hyodysenteriaemediated hemolysis of red blood cells by 50% or more. In this assay, BHI (Brain heart infusion; Difco) medium was supplemented with cysteine-HCl (0.1%) as a reducing agent, resazurin as a redox indicator (0.0001 %), fetal bovine serum (12%), and washed bovine red blood cells (7%). The compound solution was serially diluted two fold by automatic pipette in a 96 well microtiter format. After inoculation with S. hyodysenteriae (final cell density was approximately 106CFU/ml), the microtiter plates were incubated anaerobically at 39°C for 24 hours in an anaerobic chamber (Coy Laboratory). The minimum inhibition concentration (MIC) was determined as the concentration of the first well showing activity.
Anti-bacterial Spectrum Agar Dilution Assay
Seven aerobic animal pathogens and four anaerobic animal pathogens were tested. BHI agar and 5% bovine blood tryptose agar were used for the aerobic bacteria and anaerobic bacteria, respectively. The test compound was first dissolved into 1 ml absolute ethanol, then BHI broth was added to adjust to the appropriate starting concentration of each test compound.This original solution was serially diluted two-fold and 1 ml of each VOL.50 NO.6 THE JOURNAL OF ANTIBIOTICS dilution solution was mixed well with molten agar medium and solidified to make a series of drug containing plates. The precultures of all the test bacteria were re-inoculated into fresh media on the morning of the assay and were inoculated onto the drug-containing plates using a Steer's replicator after adjusting their OD600nmto 0.2. The BHI plates inoculated with aerobic bacteria were incubated at 37°C overnight and the blood plates with anaerobic bacteria were incubated in an anaerobic chamber (N2 80%, H2 10%, and CO2 10%) at 39°C for 48 hours. The MICs were determined as the lowest concentration of test compoundwhich inhibited growth completely.
Anti-£. coli Microdilution Assay
The isogenic E. coli strains W4680 and WZM120 (AacrAB) were used in this assay to test the effect of AcrA/B deletion mutation on hygromycin A suscepti- 
Results
The structure of the hygromycin A analogs tested in the PSI assay are listed in to the above analogs, chloramphenicol and streptomycin were tested as controls. These analogs and controls were also tested aginst S. hyodysenteriae whole cell assays to obtain anti-S. hyodysentreae activity (MICs). The results of both PSI assays (IC50) and whole cell assays (MIC) are presented in Table 1 . The IC5Os ofhygromycin A and chloramphenicol were 0.6,um and 7.5/^m, respectively and hygromycin A was about ten times more potent than chloramphenicol. MICsof both antibiotics against S. hyodysenteriae were the same in the microdilution assay (0.78^g/ml) or very similar in the agar dilution assay (1.56^g/ml and 0.78^g/ml, Table 2 . Hygromycin A and its analogs possess moderate antibacterial spectrum against several animal pathogens but lack anti-Gfam-negative enteric lOOO jug/ml 1 00 /zg/ml 200/400 /ig/ml 6.25 /ig/ml 15.6 jug/ml 3.13 //g/ml 3. 13 /ig/ml 0.78/1.56/*g/ml activity.
In contrast, chloramphenicol, which is a less potent protein synthesis inhibitor than hygromycin A, showedexcellent broad spectrum as well as potency. The antibacterial activity of hygromycin A (MIC) was measured against AcrA/B deletion mutant (WZM120 AacrAB) and its isogenic parent strain (W4680). Erythromycin, novobiocin and chloramphenicol were used as controls. The results are presented in Table 3 . The significant reduction in MICs of both erythromycin and novobiocin (32 to 128 fold) were observed in AcrA/B deletion mutant (WZM120) compared to its parent strain (W4680) as reported previously13). The MIC of hygromycin A was equally reduced in the AacrABmutant strain (MIC= 15.6jUg/ml vs. 1000fig/ml, 64 fold reduction). These results indicate that hygromycin A is a substrate of the Acr A/B efflux pump.
Discussion
Structure Activity Relationships
The following structure-activity relationships of hygromycin A were derived from the in vitro cell free PSI and whole cell assays: 1. The aminocyclitol portion of hygromycin A is enough to gain moderate antibacterial activity albeit the intact aminocyclitol gave the best antibacterial activity10). The latter study to explore the aminocyclitol region was carried out using 4'-0-aHyl aglycone of hygromycin A instead of hygromycin A itself. Therefore there is a possibility that the aminocyclitol is essential only in combination with 6-deoxy-5-keto-D-arabino-hexofuranose moiety; 4/-allyloxy-3/-hydroxy-2-methylcinnamic acid (CP-123,800, Fig. 1 Replacing 6-deoxy-5-keto-D-arabino-hexofuranose with arabino-hexopyranose (CP-1 17,542) at the 4' position did not regain antibacterial activity in vitro or in the cell free system (MIC >200/xg/ml and IC50 > 1400/im). The lack of antibacterial activity of CP-1 17,542 may be originated from the difference in the stereochemistry of sugar moiety. In addition to the different ring size, the stereochemistry of both hydroxyl groups at 2" and 3" is opposite from that of the naturally occurring 6-deoxy-5-keto-Darabino-hexofuranose (Fig. 1 ). However, 6-deoxy-5-keto-D-arabino-hexofuranose moiety can be replaced by an allyl group without losing antibacterial activity (CP-1 1 1,905). The extensive study on 4' position of hygromycin A by semi-synthetic approach and anti-S. hyodysenteriae whole cell assay revealed that small lipophilic groups, which are less than five methylene groups, lead to the most active 4' substituted analogs and longer aliphatic chain substitutions at this position reduced antibacterial activity7'1 1 > 12).
3. The OHgroup at the 3' position of the allyl analog (CP-ll 1,905) can be replaced by an NH2 without losing in vitro antibacterial activity (CP-113,056, MIC 0.78 jug/ml).
The replacement with other group such as hydrogen, methyl, and 0-methyl reduced in vitro antibacterial activity7). However, the intrinsic protein synthesis inhibition activity of CP-1 13,056 seems to be less than that ofCP-111,905 (IC50, 64fiM vs. 28ptM). The A. pleuropneumoniae and slightly increased potency against S. hyodysentenae (Table 2 ). The overall structureactivity relations based on PSI assay and whole cell assay have been summarizedin Fig. 2 . These conclusions were consistent with the SARreported previously based on the whole cell assays with over one hundred analogs synthesized6~12). These discrepancies may be explained by the difference in transport efficiency of both antibiotics into bacterial cells. There are three factors influencing transport of antibiotics into Gram-negative bacterial cells. These are the outer membranebarrier, the efflux pumpmechanism and the inner (cytoplasmic) membranebarrier. It is well knownthat enteric Gram-negative bacteria such as E. coli and Salmonella have a less permeable outer membranecompared with other Gram-negative bacteria such as Pasteurella. This rigid outer membrane is a barrier against certain types of antibiotics such as bulky macrolides and hydrophobic fusidic acid. The S. typhimurium LT2 strain used in our spectrum assay is a deep rough mutant of lipopolysaccharide (LPS) lacking 0-side chain, outer core and one heptose in the diheptose region. This strain is more susceptible to the antibiotics mentioned above. Historically MICs of macrolides against this strain are equivalent or 2~4 times higher than against P. multocida. However, the lack of this enhancement in susceptibility of hygromycin A against Salmonella deep rough mutant strain indicates that the outer membranepermeability barrier maynot be the major reason for ineffectiveness of hygromycin A against E. coli and Salmonella. This hypothesis is further supported by the facts that hygromycin A is a hydrophilic compound and its molecular weight is 51 1 dalton, which is small enough to pass through porins (OmpC and OmpF) by passive diffusion18). Recently the universal efflux pump was identified in Pseudomonas aeruginosa (MexA/B19)) as well as in E. coli (AcrA/B20)). Many antibiotic classes can be substrates for these pumps, which provides P. aeruginosa JUNE 1997 and E. coli an intrinsic antibiotic resistance19'20). It was reported that the newly developed oxazolidinone antibiotics are a substrate of AcrA/Befflux pumpin E. coli and their lack of anti-Gram-negative aerobic activity is caused by this efflux mechanism21}. Oxazolidinones showed significantly improved susceptibility against AacrA/B E. coli mutant (MIC=4/ig/ml) compared to its parent strain (MIC >128^g/ml21)).
There is a possibility that hygromycin A is a substrate of this efflux pump likewise. In order to test this hypothesis, the antibacterial activity of hygromycin A was measured against AcrA/B deletion mutant (WZM120 AacrA/B) and its isogenic parent strain (W4680). As presented in Table 3 , MICof hygromycin A against WZM120is significantly improved compared to its isogenic parent strain (15.6^g/ml vs. 1000/zg/ml, 64 folds). These results indicate that hygromycin A is also a substrate of this efflux pumpand the ineffectiveness of hygromycin A against enteric Gram-negative bacteria E. coli and Salmonella is mainly caused by this universal efflux pump. The MICof chloramphenicol was also reduced in the AacrA/B mutant strain but the degree of reduction in MICwas muchless than for erythromycin, novobiocin and hygromycin A (4~8 fold). Chloramphenicol may be a less favorable substrate for the Acr ABefflux pump. Hygromycin A is still less potent against AacrA/B mutant than chloramphenicol (15.6/xg/ml vs. 0.78/1.56jUg/ml, 10~20 fold) in spite of its 10-fold higher potency in the cell free system. One explanation could be that hygromycin A passes through the cytoplasmic (inner) membraneless efficiently than chloramphenicol in enteric
Gram-negative bacteria, in which case lower permeability through the cytoplasmic membraneand significant efflux activity could combine to render hygromycin A totally inactive against enteric Gram-negative bacteria.
In contrast with the enteric Gram-negative bacteria, hygromycin A showed moderate antibacterial activity against both respiratory Gram-negative bacteria P. haemolytica and P. multocida (12.5/ig/ml and 1.56 jUg/ml, Table 2 ). These respiratory Gram-negative bacteria may not possess Acr A/B type universal efflux pump, or hygromycin A maynot be a substrate for the efflux pump of these bacteria due to different substrate specificity.
